A major metabolite of PGD2 found in human and mouse urine at levels of approximately 1.5 and 8.1 ng/mg creatinine, respectively.

(±)14(15)-EET-d11 contains 11 deuterium atoms at the 16, 16', 17, 17', 18, 18' ,19, 19' ,20, 20, and 20 positions. It is intended for use as an internal standard for the quantification of (±)14(15)-EET (Item No. 50651) by GC- or LC-MS.

A potent anti-fungal antibiotic that can directly block nuclear transport by inhibiting the action of CRM1.

5(S)-HETrE is produced by the action of 5-LO when mead acid is the substrate. There are no literature reports of the biological activity or further metabolic fate of 5(S)-HETrE.

A major urinary metabolite of PGE2 that is excreted in guinea pig urine at a concentration range of 1.34-2.74.

An isotopically enriched form of a PUFA standard with carbon-13 occurring at positions 1, 2, 3, 4, and 5; used to study metabolic processes related to arachidonic acid by means of mass spectrometry.

A cyanobacterial toxin that targets protein and glutathione synthesis in hepatocytes (IC50s = 1.3 and 2.4 µM, respectively), inhibits uridine monophosphate synthase complex activity (Ki = 10 µM), and induces DNA damage.

A proposed anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.

Key urinary metabolite of PGD2; represents approximately 1% and 4% of the infused radiolabeled dose in monkeys and humans, respectively.

One of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

(±)5-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. It contains equal amounts of 5(S)-HETE and 5(R)-HETE. (±)5-HETE induces the aggregation of isolated neutrophils with an IC₅₀ value of 200 nM.

A derivative of (±)8(9)-EET which is stable enough to ship and handle routinely.

A potential cytochrome P450 metabolite of N-arachidonoyl taurine that may activate TRPV1 and TRPV4.

A metabolite of (±)12(13)-EpOME.

11-trans LTC4 is a C-11 double bond isomer of LTC4. LTC4 undergoes slow temperature-dependent isomerization to 11-trans LTC4 during storage. 11-trans LTC4 is produced in smaller amounts relative to LTC4 in ionophore-stimulated HMC-1 cells (a human mast cell line) and equine eosinophils, but not in…

A potential metabolite of PGD2, presumably produced from the known metabolite 13,14-dihydro-15-keto PGD2.

8(S)-HETrE is a monohydroxy PUFA produced by rabbit neutrophil lipoxygenase when DGLA is used as a substrate. Although the biological activities of 8(S)-HETrE have not been well characterized, it is expected to behave similarly to 8(S)-HETE.

Less potent than AEA (Item No. 90050) at the CB1 receptor (Ki = 600 versus 90 nM); inhibits FAAH.

An internal standard for quantification of 13,14-dihydro-15 (R,S)-hydroxy-16,16-difluoro-Prostaglandin E1, a metabolite of a bicyclic PGE1 derivative used in the treatment of chronic constipation, by GC- or LC-mass spectrometry (MS).

A DHA epoxygenase metabolite detected in rat brain and spinal cord, as well as human serum, that acts as a substrate for sEH (Km = 5.1 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

An epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo; its effects of remain to be determined.

A minor CYP450 metabolite of arachidonic acid that stimulates vasodilation of rabbit kidney.

(±)12-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)12-HETE is similar to that of its constituent enantiomers (Item Nos. 34560 and 34570). It aggregates neutrophils with an EC₅₀…

An internal standard for the quantification of (±)14(15)-DiHET by GC- or LC-MS.

(±)8-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

A 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-LO and sEH co-incubated with DHA; reduces neutrophil infiltration in a mouse model of peritonitis and enhances human macrophage phagocytosis of zymosan A.

A DHA-derived product first identified in mouse inflammatory exudates; reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation; enhances macrophage phagocytosis and efferocytosis.

A DHA epoxygenase metabolite found in rat brain and spinal cord that acts as a preferred substrate for sEH (Km = 3.2 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

Biosynthesis of LTA3 occurs from 5,8,11-eicosatrienoic acid via the 5-LO pathway{689} and it is the putative intermediate in the biosynthesis of 3-series leukotrienes. LTA3 as a free acid is highly unstable. The methyl ester is stable and can be readily hydrolyzed to the free acid as needed.

The racemic version of a CYP450 metabolite of arachidonic acid that dose-dependently stimulates vasodilation of the rabbit kidney.

A major CYP450 metabolite of arachidonic acid that is released from the kidney in response to angiotensin II; a potent vasodilator of renal preglomerular vessels; blocks 20-HETE-induced vasoconstriction of renal arterioles at 1 µM.